Quinolones: Synthesis and Antibacterial Activity by Pintilie Lucia
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
12 
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1. Introduction  
After the concept of selective toxicity in chemotherapy was introduced at the beginning of the 
20th century, (Ehrlich, 1913), classes of substances with antibacterial properties, produced by 
microorganisms or created through synthesis were obtained. After the discovery of penicillin, 
the first antibiotic introduced in clinical use in man in 1940s, a large number of different types 
of antibiotics were produced. Antibiotics such as beta-lactams, macrolides, aminoglycozides 
and tetracyclines were discovered and introduced during an extremely short period. These 
were obtained either by isolation from fungi or by chemically modification of the naturally 
isolated substrates. These dominated the antimicrobial industry, while synthetically obtained 
substances only played a minor role. (Chu & Fernandes, 1991) 
In 1962, G. Y. Lesher and his collaborators introduced the first quinolone derivative, 
nalidixic acid (1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilyc acid), (1, 
Lesher et al. 1962) which had moderate activity against gram-negative organisms and was 
used for treating urinary tract infections. In the following years, a large gamma of 
derivatives from common elements were synthesized, which could be grouped by: cinoline 
(cinoxacin), pyrido-pyrimidine (pipemidic acid; piromidic acid), naphthyridine (nalidixic 
acid) and quinolones (oxolinic acid, miloxacin , tioxacin, etc.). These derivatives, with 
differentiated structures, have 2 common pharmacological properties, which allowed them 
to be classified as first generation biologically active derivatives with quinolone structure. 
The two common characteristics for first generation quinolones are:  
- a narrow antibacterial spectrum, designed especially for enterobacteriaceae; 
- a pharmacokinetic which allows for rapid elimination and reduced tissue absorption, 
only allowing them to be used as urinary antiseptics. 
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Fig. 1. First-generation quinolones. 
The success of first generation quinolones spurred the research in this area, which led to the 
obtainment through synthesis, after 1980, of a new series of compounds with stronger 
antibacterial properties and a broader spectrum of antibacterial activity which included 
gram positive and gram negative organisms, and which where defined by their ability to be 
applied on all localized infections. Koga and his collaborators introduced Norfloxacin into 
clinical use in 1980, the first quinolone with a fluorine  atom substituted at the C-6 position 
and a piperazine C-7. Norfloxacin (Koga et al. 1980) was the first quinolone with increased 
antimicrobial activity, acting on a large spectrum of gram positive and gram negative 
microorganisms, including Pseudomonas aeruginosa. 
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Fig. 2. Second-generation quinolones. 
Research in the field of derivatives with a quinolone structure have lead to new compounds 
obtained recently, which have been classified as third and fourth generation systemic 
quinolones, largely effective against Staphilococcus aureus. Their large antibacterial 
spectrum includes anaerobes, Chlamydia and Mycoplasma. (Brighty & Gootz, 2000) 
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Fig. 3. Third- generation quinolones. 
The four generations have the following common aspects: an identical mechanism of action 
by inhibition the A subunit of DNA-gyrasa, an exclusively chromosomal bacteria resistance 
and some similar bacteria effects: photo toxicity, neurotoxicity, cartilage toxicity. 
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Fig. 4. Fourth- generation quinolones. 
Until now a large number of antibacterial substances belonging to the above mentioned 
class have been used in medicine. Quinolones are used when treating infections of the 
urinary tract, the respiratory tract, intestinal infections, ear/nose/throat infections, STD’s, 
soft tissue and skin infections, meningitis caused by gram negative and Staphilococci 
bacteria, liver and bile infections, septicemia and endocarditis, prophylaxis and surgical 
infections and on patients with immune deficiencies.  
 
Antimicrobial Agents 
 
258 
The mechanism of action of quinolone antibacterial agents involves the inhibition of DNA 
gyrase (a bacterial topoisomerase II) resulting in a rapid bactericidal effect. 
The antibacterial activity of quinolones (measured in terms of MIC), however, is the result of 
the combination of bacterial cell penetration and DNA gyrase inhibitory activity. The 
antibacterial activity of quinolones depends not only on the bicyclic heteroaromatic system 
combining the 1,4-dihydro-4-pyridine-3-carboxylic acid moiety and an aromatic ring, but 
also on the nature of the peripheral substituents and their spatial relationships. These 
substituents exert their influence on bacterial activity by providing additional affinity for 
bacterial enzimes, enhancing cell penetration or altering the pharmacokinetics. 
The research for an ideal quinolone continues worldwide. Such a quinolone must be 
biologically active on a large spectrum of gram positive and gram negative bacteria, aerobes 
and anaerobes  and mycobacteria, must have as few side effects as possible, excellent 
solubility in water and oral bioavailability.  
In figure 5, the most common synthesized chemical variations obtained during the research 
for new quinolones with antibacterial activity, are visible. 
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Fig. 5. Structural variations of the most recent quinolones. 
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2. Quinolones: Structural features  and method of synthesis 
2.1 Structural features 
Quinolone derivatives are an important class of antibacterial agents with wide action. Basic 
structure of these compounds (Figure 6) is a bicyclic structure, which contains a ring of type 
A 4-piridinona combined with aromatic or heteroaromatic ring B. The ring type A 4- 
piridinona is a ring with absolute necessity: an unsaturation in position 2-3, a free acid 
function in position 3 and a substituent at nitrogen in position 1. 
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Fig. 6. Basic structure of quinolones. 
2.1.1 Bicyclic quinolones 
Position 1 
The studies on quinolones indicated that in order for the compound to have antibacterial 
activity, the N-1 position requires a substituent. Many quinolones  contain in N-position : 
ethyl (norfloxacin, pefloxacin, lomefloxacin) , fluoroethyl (fleroxacin), vinyl, clloroethyl, 
trifluoroethyl, aminoethyl,, cyclopropyl (ciprofloxacin), t-butyl, bicyclopentyl,p- 
fluorophenyl,2,4-difluorophenyl (Scott 1997) 
Position 2 
Quinolones contain at C-2 hydrogen (R2=H). The  replacement at hydrogen has generally 
proven to be disadvantageous. However, some compounds containing a suitable C-1, C-2 
ringhave recently been shown to possess biological activity. (Figure7 -Segawa 1992) (Figure 
8 – Scott 1997)  
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Fig. 7. Basic structure of bicyclic quinolones. 
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                                        R = H, methyl, ethyl, substituted phenyl 
                                        R6= F, Cl 
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Fig. 8. 7-Substituted-6-halo-4-oxo-4H-[1,3]-thiazeto[3,2]quinolin-3-carboxilyc acid. 
Position 3 
The C-3 carboxylic acid  moiety is most commonly encountered. (Chu &Fernandes1991) . In 
the late of 1980s, a modification was described that eliminated the need for C-3 carboxylic 
acid. A fused izothiazolone ring was identified as  serving as a carboxylic acid mimic,The 
compound A-62824 (Figure 9) have been found with biological activity. 
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Fig. 9. Quinolones with sulfur substituent at C-2. 
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Fig. 10. A-62824. 
Position 4 
The C-4 oxo group of the quinolones nucleus is generally considered to be essential for 
antibacterial activity. 
Position 5 
The choice of the C-5 substituent appears to be dictated by the the steric regulations and the 
nature of the N-1 and C-8 substituent (Chu &Fernandes1991). (R5 = methyl, halogen, amino 
when X = CF). 
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Position 6 
The nature of the C-6 substituent have a great impact on the DNA-gyrase inhibitory activity 
and cell penetration. (Domagala et al. 1986). The R6 can be H, Cl, F, NO2, NH2, CN, 
CH3SCH3, COCH3 ) (Koga et al. 1980) 
Position 7 
The choice of the C-7 substituent is a key issue which continues to guide the design of new 
antibacterial quinolones. The R7 can be substituted/unsubstituted piperazines, 
aminopyrrolidines, aminoalkylpyrrolidines, (Figure 5) (Chu & Fernandes 1991) (Scott 1997). 
Position 8 
The most common variations at the C-8 position is hydrogen atom (X= CH) or a nitrogen 
atom(a naphthyridine) (X=N). However, compact, liophilic group (X = CF,C-CF3,, CCl, C-
OCH3) increase the antibacterial activity. (Chu & Fernandes 1991) (Scott  1997). 
2.2 Method of synthesis 
Gould-Jacobs method  
The quinolones are of synthetic origin. (Chu & Fernandes, 1991). The most common 
synthetic  methodology to prepare quinolone derivatives is  Gould-Jacobs method (Figure 
11).  This method is used mainly for synthesis of compounds with N-1 alkyl substituents, 
and consists in the condensation of anilines (II) with diethyl ethoxymethylenemalonate 
(EMME) and cyclization of the obtained anilinomethylenemalonate. Termal cyclization can 
be carried out in dowterm (Koga, et al.1980), clorsulfonic acid, oleum acid or a mixture of 
clorosulfonic acid and oleum acid (Saukaita & Gupton, 1996). The key intermediary 
obtained (IV or X) will undergo a alkylation (Koga et al. 1980), cycloalkylation with bromo-
cyclopropane (Kazimierozaack & Pyznar, 1987), (Sanjose&Ulpiano 1986),  or with 1-bromo-
1-ethoxy-cyclopropane, arylation with para-nitro-clorofenil or 2,4-dinitro-clorofenil (Raddl & 
Zikan, 1989) in order to insert the substituent  in position 1 of  the quinolone nucleus. The 
ethyl esther (V) undergoes a hydrolysis reaction, and the quinoline-3-carboxylic acid  (VI), 
following regiospecific substitution  of the 7-chloro group  leads to the final compounds 
(VIII).  Figure 11 illustrates also, methods for synthesis of 1-cyclopropyl-quinolones starting 
to  anilines of formula II.Anilines (II) is reacted with 1-bromo-1-ethoxy-cyclopropane 
(Ramos & Garcia 1994)(Scriewer et al. 1988) or a cyclopropyl-metalic compound (McGuirk 
1989). Alternatively, N-ethyl substituted anilines of formula XV may be formed by reductive 
amination with an appropiate aldehyde and a suitable reducing agent: diborane, palladium 
on carbon with hydrogen, sodium borohydride or sodium cyanoborohidride (McGuirk 
1989) (Ramos 1994). N-isopropyl substituted quinolones may be form by alkylation with 
isopropylbromide (Pintilie et al. Sept. 2009), (Pintilie et al, oct.2009),(Pintilie et al. 2010), of 
compounds IV. (Figure 11). 
The modified Gould-Jacobs method will also be used, where the diethyl 
ethoxymethylenemalonate reacts with monosubstituted N aniline (XVII) (Figure 12). The 
aniline (XVII) is obtained by reductive amination of ketones and aldehydes with sodium 
borohydride-acetic acid (Itoh & Kato 1984) or  triacetoxyborohydride. (Pintilie et al.2009). 
(Pintilie et al. 2010). 
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Fig. 12. The modified Gould-Jacobs method. 
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Fig. 13. Method requiers the reaction of isatoic anhydride with sodium ethyl formyl acetate 
Intramolecular nucleophilic displacement cyclization route to quinolones (a) 
An efficient and regiospecific synthesis via an intramolecular nucleophilic displacement 
cyclization reaction  was reported. (Chu,1985) (Figure 14).  
Key compund (III) can be obtained by: 
• reaction of benzoic acid chloride (I)  with ethyl malonic acid; the compound (II)  give 
the  compund (III).(Petersen & Grohe 1984a), (Petersen & Grohe 1984b), 
• acetophenone (Ia) is condensed  with diethyl carbonate in the presence of sodium 
hydride(Chu et al. 1985) 
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Fig. 14. Intramolecular nucleophilic displacement cyclization route to quinolones (a). 
Intermediates (III) reacts with acetic anhydride in the presence trietilortoformiate  to 
produce  3-ethoxy-2-benzoyl-ethyl acrylate (IV). Compound (IV) is further reacted  with an  
appropriate amine in dichloromethane at room temperature to provide  3-anilino-2-benzoyl-
ethyl acrylate (IVa). 
Compound (IVa) can be also obtained directly from benzoic acid chloride (I).  (Chu & 
Fernandes 1991). 
Treatment with a base induces cyclization to produce the quinolone (V).  
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Intramolecular nucleophilic displacement cyclization route to quinolones (b)  
A synthesis method similar to that described above is shown in Figure 15. This method  
involves intramolecular cyclization of the  compound (VIII).(Egawa et al. 1987). 
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Fig. 15. Intramolecular nucleophilic displacement cyclization route to quinolones (b). 
2.3 Structure of the new compounds 
This paper presents experimental data regarding the synthesis of several quinolones with 
general formula: (Figure 16) 
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Fig. 16. The structure of the new compounds. 
R1 = ethyl, isopropyl, 2-buthyl, 2-penthyl, benzyl, alyl, p-nitro-phenyl, p-amino-phenyl; 
R6 = hydrogen, fluor, chlor, methyl; 
R7 = 3-methyl-piperazinyl, 4-methyl-piperazinyl, piperidinyl, 3-methyl-piperidinyl,  
4-methyl-piperidinyl, pirolidinyl, morpholinyl, homopiperazinyl; 
R8 = hydrogen,chlor, methyl. methoxy, nitro 
2.4 Synthesis pathway 
The synthesis of the novel quinolones followed a Gould-Jacobs cyclization process (Figure 
17). An appropriate unsubstituted aniline (1) is reacted with diethylethoxy methylene 
malonate (EMME) to produce the resultant anilinomethylenemalonate (2). A subsequent 
thermal process induces Gould-Jacobs cyclization to afford the corresponding 4-hidroxy-
quinoline-3-carboxylate ester (3). (R6 = fluoro, chloro, methyl, hydrogen) (Pintilie et al. 
2009a) (Pintilie et al. 2009b),(Pintilie et al. 2010). 
6
78
1 2 3
4
5
N
O
R1
CO2HR6
R7
R8
R6
Cl NH2
R8
EMME
R6
Cl
R8
NH
CO2C2H5
CO2C2H5 Dowterm
N
OH
CO2C2H5
R6
Cl
R8
R6
Cl
R8
NH
R1
EMME
N
R1
CO2C2H5
CO2C2H5
R6
Cl
R8
N
R6
Cl
O
CO2C2H5
R1R8
PPA
N
O
R1
R6
Cl
R8
CO2H
1300 C
1,5 h
2500C
45 min.
1450C
1,5 h
90-1000C
DES/Rhal
K2CO3
DMF
DES / NaOH
HCl
1.
2.
NaOH
AcOH
heterocycle
- aq.
 
Fig. 17. Synthesis of the new quinolones. 
The following operation is the alkylation of the 4-hidroxy-quinoline-3-carboxylate ester (3). 
which is usually accomplished by reaction with a suitable alkyl halide, dialkyl sulphates, aril 
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halide to produce the qinolone 3-carboxylate ester (6). (R1 = ethyl, alyl, benzyl, p-nitrophenyl) 
(Pintilie et al. 2003a) (Pintilie et al. 2003b),(Pintilie et al. 2003c)(Pintilie & Nita 2011). 
A modified approach resorts to the use of a monosubstitued aniline (4) as a starting material 
which avoids subsequent N-1-amine alkylation (R1 = isopropyl, 2-butyl, 2-pentyl). (Pintilie 
et al. 2009a) (Pintilie et al. 2009b),(Pintilie et al. 2010). A strong acid (such as polyphosphoric 
acid) is often needed to induce cyclization directly resulting in the formation of N-isopropyl-
4-oxo-quinolone-3-carboxylate ester (6) (R1 = isopropyl, 2-butyl, 2-pentyl). In either case, the 
final manipulation is acid or basic hydrolysis to cleave the ester generating the biologically 
active free carboxylic acid (7). The biologically active free carboxylic acid (7) was also 
obtained from the corresponding 4-hidroxy-quinoline-3-carboxylate ester (3) by alkylation 
with dialkyl sulphates in presence of alkali, for example the reaction it can conveniently be 
carried out in aqueous 40 % sodium hydroxide solution. The displacement of 7-chloro group 
with a heterocycle yielded compounds (8).  
The synthesis of new 1-aryl quinoline-3-carboxilyc acids is according  Figure 18. compound 
(3) (R6=F,Cl,CH3) is direct N-arylation. Treatment of  (3) with potasium carbonate in DMSO 
and p-fluoro-nitrobenzene yielded 9). The esters were hydrolized to the appropiate acids 
(10) by refluxing with a mixture of hydrochloric and acetic acids. Upon treatment with a 
heterocycle yielded compounds (11). The 1-(p-amino-phenyl)-quinoline-3-carboxylic acids 
(12) can be prepared by a common reduction of nitro group using sodium dithionite. 
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Fig. 18. Sinthesys of 1-aryl-quinolones. 
The sinthesys of the new 8-substituted quinoline-3-carboxylic acids is according Figure 19. 
8-Chloro-quinoline-3-carboxylic acids (13) was synthesized from 8-unsubstituted qinoline-3-
carboxilyc acids by chlorination with sulfuryl chloride. 8-Methoxy-quinoline-3-carboxilyc 
acids (14) was prepared allowing compound (13) to act with alkali metalic alcholate. 
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Fig. 19. Sinthesys of the new 8-substituted quinoline-3-carboxylic acids. 
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2.5 New compounds: Structure and antimicrobial activity 
2.5.1 Structure of the new compunds 
A series of new 4-oxo-1,4-dihydro-quinoline-3-carboxylic acids was synthesized. (Figure 20) 
(Table 1). 
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Fig. 20.  Structure of the new compounds. 
 
Quinolones R1 R6 R7 R8 m.p. (0C) Reference 
Q 83 
C18H21FN2O3 
ethyl F 4-methyl-piperidin-1-yl H 235-237 
Pintilie et 
al. (2003b) 
Q 85 
C18H20 Cl FN2O3
ethyl F 4-methyl-piperidin-1-yl Cl 201-202,5 
Pintilie et 
al. (2003b) 
PQ 1 
C19H23FN2O4 
ethyl F 4-methyl-piperidin-1-yl OCH3 170 
Pintilie et 
al. (2003b) 
PQ 12 
C19H23FN2O3 
iIso-propyl F 4-methyl-piperidin-1-yl H 253 
Pintilie et 
al. (2003b) 
PQ 11 
C23H23FN2O3 
benzyl F 4-methyl-piperidin-1-yl H 240-242 
Pintilie et 
al. (2003b) 
PQ 4 
C19H21FN2O3 
alyl F 4-methyl-piperidin-1-yl H 168-170 
Pintilie et 
al. (2003b) 
FPQ 24 
C18H21FN2O3 
ethyl F 3-methyl-piperidin-1-yl H 189,4 
Pintilie et 
al. (2009b) 
6ClPQ 24 
C18H21ClN2O3 
ethyl Cl 3-methyl-piperidin-1-yl H 
216,4-
218,4
Pintilie et 
al. (2009b) 
PQ 24 
C19H23FN2O3 
iIso-propyl F 3-methyl-piperidin-1-yl H 
209,1-
211,7
Pintilie et 
al. (2009b) 
PQ 22 
C18H21FN3O3 
iIso-propyl F 3-methyl-piperazin-1-yl H 215-218 
Pintilie et 
al. (2009b) 
PQ 23 
C17H19FN2O4 
iIso-propyl F morpholin-1-yl H 266-268 
Pintilie et 
al. (2009b) 
FPQ 25 
C16H17FN2O4 
ethyl F morpholin-1-yl H 
257,4-
258,7
Pintilie et 
al. (2009b) 
6ClPQ 25 
C16H17ClN2O4 
ethyl Cl morpholin-1-yl H 
267,1-
269,2
Pintilie et 
al. (2009b) 
6ClPQ 27 
C17H20FN3O3 
ethyl Cl 3-methyl-piperazin-1-yl H 
170,5-
171,4
Pintilie et 
al. (2009b) 
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Quinolones R1 R6 R7 R8 m.p. (0C) Reference 
FPQ 28 
C16H16ClFN2O4
ethyl F morpholin-1-yl Cl 244,6-244 
Pintilie et 
al. (2009b) 
6MeQ 83 
C19H24N2O3 
ethyl CH3 4-methyl-piperidin-1-yl H 240-242 
Pintilie et 
al. (2003a) 
6MePQ 12 
C20H26N2O3 
iIso-propyl CH3 4-methyl-piperidin-1-yl H 234-235 
Pintilie et 
al. (2003a) 
6MePQ 11 
C24H26N2O3 
benzyl CH3 4-methyl-piperidin-1-yl H 218-220 
Pintilie et 
al. (2003a) 
6MePQ 4 
C20H24N2O3 
alyl CH3 4-methyl-piperidin-1-yl H 244-246 
Pintilie et 
al. (2003a) 
HQ 83 
C18H22FN2O3 
ethyl H 4-methyl-piperidin-1-yl H 240-242 
Pintilie et 
al. (2003c) 
HPQ 12 
C19H24N2O3 
iIso-propyl H 4-methyl-piperidin-1-yl H 234-235 
Pintilie et 
al. (2003c) 
HPQ 11 
C23H24N2O3 
benzyl H 4-methyl-piperidin-1-yl H 218-220 
Pintilie et 
al. (2003c) 
HPQ 4 
C19H22N2O3 
alyl H 4-methyl-piperidin-1-yl H 244-246 
Pintilie et 
al. (2003c) 
HPQ 21 
C18H23N3O3 
iIso-propyl H 4-methyl-piperazin-1-yl H 239-240 
Pintilie et 
al. (2009a) 
HPQ 24 
C18H22N2O3 
ethyl H 3-methyl-piperidin-1-yl H 
190,1-
192,1 
Pintilie et 
al. (2009a) 
HPQ 25 
C16H18N2O4 
ethyl H morpholin-1-yl H 267,3-269 
Pintilie et 
al. (2009a) 
HPQ 27 
C17H21N3O3 
ethyl H 3-methyl-piperazin-1-yl H 
191,3-
192,6 
Pintilie et 
al. (2009a) 
HPQ 31 
C19H24N2O3 
2-butyl H 4-methyl-piperidin-1-yl H 181,4-183 
Pintilie et 
al. (2009a) 
HPQ 51 
C19H24N2O3 
2-pentyl H 4-methyl-piperidin-1-yl H 
138,5-
140,5 
Pintilie et 
al. (2009a) 
PQ 3 
C22H20FN3O5 
p-nitro-
phenyl 
F 4-methyl-piperidin-1-yl H 204-206 
Pintilie& 
Nita (2011) 
PQ 7 
C21H19FN4O5 
p-nitro-
phenyl 
F Homopiperazin-1-yl H 128-130 
Pintilie& 
Nita (2011) 
6ClPQ 3 
C22H20ClN3O5 
p-nitro-
phenyl 
Cl 4-methyl-piperidin-1-yl H 202-205 
Pintilie& 
Nita (2011) 
6MePQ 3 
C23H23N3O5 
p-nitro-
phenyl 
CH3 4-methyl-piperidin-1-yl H 222-224 
Pintilie& 
Nita (2011) 
APQ 3 
C22H22FN3O3 
p-amino-
phenyl 
F 4-methyl-piperidin-1-yl H 284-285,5 
Pintilie& 
Nita (2011) 
A6MePQ 3 
C23H22N3O3 
p-amino-
phenyl 
CH3 4-methyl-piperidin-1-yl H 250-253 
Pintilie& 
Nita (2011) 
Table 1. 4-Oxo- 1,4-dihydro-quinoline-3-carboxylic acids synthesized in this paper. 
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2.5.2 Antibacterial activity of the new compunds 
The new compounds were evaluated for “in vitro” activity by determining minimum 
inhibitory concentration against of bacteria Escherichia. Coli, Staphylococcus. Aureus and 
Pseudomonas .aeruginosa, by agar dilution method (Buiuc 1998) (NCCLS 2003). (Table 2). 
 
Quinolone 
Minimum inhibitory concentration 
µg/ml Referances 
E. coli S. aureus P. aeruginosa 
Q 83 3,12 (a) 1,56 (c) 6,25 (e) Pintilie et al. (2003b) 
Q 85 3,12 (a) 0,39 (c) 6,25  (e) Pintilie et al. (2003b) 
PQ 1 3,12 (a) 0,78 (c) 3,12  (e) Pintilie et al. (2003b) 
PQ 4 12,5 (a) 1,56 (c) 6,25  (e) Pintilie et al. (2003b) 
FPQ 24 2,00 (a) 0,50 (b) 32,00 (d) Pintilie et al. (2009b) 
6ClPQ 24 8,00 (a) 2,00 (b) >128 (d) Pintilie et al. (2009b) 
PQ 24 8,00 (a) 2,00 (b) 64,00 (d) Pintilie et al. (2009b) 
PQ 22 0,50 (a) 4,00 (b) 8,00 (d) Pintilie et al. (2009b) 
6ClPQ 25 4,00 (a) 2,00 (b) 128 (d) Pintilie et al. (2009b) 
FPQ 25 0,125 (a) 0,06  (b) 8,00 (d) Pintilie et al. (2009b) 
FPQ 28 0,125 (a) 0,06  (b) 8,00 (d) Pintilie et al. (2009b) 
HPQ 21 8,00 (a) 64,00 (b) >128 (d) Pintilie et al. (2009a) 
HPQ 25 8,00 (a) 64,00 (b) >128 (d) Pintilie et al. (2009a) 
HPQ 27 >128 (a) 32,00 (b) >128 (d) Pintilie et al. (2009a) 
PQ 3 12,50  (a) 25,00 (c) 12,50 (e) Pintilie& Nita (2011) 
APQ 3 12,50  (a) 0,78 (c) 12,50 (e) Pintilie& Nita (2011) 
PQ 7 12,50  (a) 3,12 (c) 12,50 (e) Pintilie& Nita (2011) 
a. Escherichia. coli ATCC 25922, b. Staphylococcus. aureus ATCC29213, c. Staphylococcus. aureus ATCC29223, 
d. Pseudomonas .aeruginosa ATCC27813,e. Pseudomonas .aeruginosa ATCC27853 
Table 2. “In vitro” antibacterial activity of the new quinolones. 
3. Conclusion  
In conclusion, were synthesized new quinolones and was investigated their antibacterial 
activity. The results indicate that substituent combinations in the quinolone ring, might 
produce powerful antibacterial agents such as compound: FPQ-28 (1-ethyl-6-fluoro-7-
morpholinyl-8-chloro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid), (Figure 21) in 
concordance with the QSARs studies (Tarko et al. 2008),  showed excellent „in vitro” 
activity against E. Coli ATCC 25922 (MIC 0,125 µg/mL) and S.aureus ATCC29213 (MIC 
0,06 µg/mL). 
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Fig. 21. 1-Ethyl-6-fluoro-7-morpholinyl-8-chloro-1,4-dihydro-4-oxo-quinoline-3-carboxylic 
acid –FPQ 28 
1H-NMR(dmso-d6, δ ppm, J Hz): 8.97(s, 1H, H-2); 8.07(d, 1H, H-5, 11.8); 4.89(q, 2H, H-17, 
7.2); 3.82(m, 4H, sist. A2B2, H-13-15); 3.37(m, 4H, sist. A2B2, H-12-16); 1.46(t, 3H, H-18, 7.2). 
13C-NMR(dmso-d6, δ ppm, J Hz): 175.56(C-4); 166.12(C-21); 154.95(d, J(13C-19F)=254.8, C-
6);158.37(Cq); 153.04(C-2); 125.94(Cq); 124.76(Cq); 116.86(Cq); 111.57(d, J(13C-19F)=23.5, C-5); 
98.35(C-3); 67.23(C-13-15); 53.64(C-12-16); 51.58(C-17); 16.14(C-18). 
FT-IR(solid in ATR, ν cm-1): 3056; 2957; 2895; 2849; 1717; 1615; 1558; 1532; 1492; 1435; 1376; 
1300; 1253; 1207; 1102; 1033; 980; 920; 890; 846; 803; 740; 651; 528; 464. 
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